A novel approach for treating B-cell lymphoma by inhibition of the E3 ligase E6AP

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1026988

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

B-cell lymphoma is the most common type blood cancer diagnosed in Australia, and Australia's fifth most common cancer. Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a leading cause of cancer-related mortality. Our pilot studies reveal a novel approach to treatment of B-cell lymphoma by inhibiting an enzyme that destroys our natural mechanism of defense against cancer. In this study we will test the efficacy of this novel treatment.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $624,846.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anticancer drug | cancer chemotherapeutic agents | haematological malignancy | human malignant B-cell lymphoma | lymphoma | molecular oncology | p53 | protein degradation | tumour suppressor gene

Related Links